Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ciaran N Kohli-Lynch

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
BMJ Open|February 23, 2022
Hypertension in the South African public healthcare system: a cost-of-illness and burden of disease studyCiaran N Kohli-Lynch, Agnes Erzse, B Rayner, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 11, 2020
The clinical utility of apoB versus LDL-C/non-HDL-CCiaran N Kohli-Lynch, George Thanassoulis, Andrew E Moran, et al.
Administration and Policy in Mental Health|January 17, 2022
Trial-Based Economic Evaluations of Supported Employment for Adults with Severe Mental Illness: A Systematic ReviewKatherine Zheng, Brocha Z Stern, Q Eileen Wafford, et al.
JAMA|April 8, 2026
Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering TherapySamuel Luebbe, Allan D Sniderman, Andrew E Moran, et al.
Health Policy and Planning|January 22, 2024
Extended cost-effectiveness analysis of interventions to improve uptake of diabetes services in South AfricaHeather L Fraser, Isabelle Feldhaus, Ijeoma P Edoka, et al.
Circulation|March 7, 2022
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular DiseaseCiaran N Kohli-Lynch, James Lewsey, Kathleen A Boyd, et al.
Hypertension (Dallas, Tex. : 1979)|May 17, 2016
Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy ModelNathalie Moise, Chen Huang, Anthony Rodgers, et al.
Journal of the American College of Cardiology|November 12, 2021
Cost-Effectiveness of Lipid-Lowering Treatments in Young AdultsCiaran N Kohli-Lynch, Brandon K Bellows, Yiyi Zhang, et al.
JAMA Cardiology|January 8, 2025
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved PopulationCiaran N Kohli-Lynch, Andrew E Moran, Dhruv S Kazi, et al.
JAMA Cardiology|August 29, 2019
Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular RiskCiaran N Kohli-Lynch, Brandon K Bellows, George Thanassoulis, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
BMJ Open|February 23, 2022
Hypertension in the South African public healthcare system: a cost-of-illness and burden of disease studyCiaran N Kohli-Lynch, Agnes Erzse, B Rayner, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|May 11, 2020
The clinical utility of apoB versus LDL-C/non-HDL-CCiaran N Kohli-Lynch, George Thanassoulis, Andrew E Moran, et al.
Administration and Policy in Mental Health|January 17, 2022
Trial-Based Economic Evaluations of Supported Employment for Adults with Severe Mental Illness: A Systematic ReviewKatherine Zheng, Brocha Z Stern, Q Eileen Wafford, et al.
JAMA|April 8, 2026
Cost-Effectiveness of ApoB, Non-HDL-C, and LDL-C Goals for Primary Prevention Lipid-Lowering TherapySamuel Luebbe, Allan D Sniderman, Andrew E Moran, et al.
Health Policy and Planning|January 22, 2024
Extended cost-effectiveness analysis of interventions to improve uptake of diabetes services in South AfricaHeather L Fraser, Isabelle Feldhaus, Ijeoma P Edoka, et al.
Circulation|March 7, 2022
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular DiseaseCiaran N Kohli-Lynch, James Lewsey, Kathleen A Boyd, et al.
Hypertension (Dallas, Tex. : 1979)|May 17, 2016
Comparative Cost-Effectiveness of Conservative or Intensive Blood Pressure Treatment Guidelines in Adults Aged 35-74 Years: The Cardiovascular Disease Policy ModelNathalie Moise, Chen Huang, Anthony Rodgers, et al.
Journal of the American College of Cardiology|November 12, 2021
Cost-Effectiveness of Lipid-Lowering Treatments in Young AdultsCiaran N Kohli-Lynch, Brandon K Bellows, Yiyi Zhang, et al.
JAMA Cardiology|January 8, 2025
Cost-Effectiveness of a Polypill for Cardiovascular Disease Prevention in an Underserved PopulationCiaran N Kohli-Lynch, Andrew E Moran, Dhruv S Kazi, et al.
JAMA Cardiology|August 29, 2019
Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular RiskCiaran N Kohli-Lynch, Brandon K Bellows, George Thanassoulis, et al.
Pageof 2